These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37205634)

  • 21. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM; Bhattacharya S; Johnson LR
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
    Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
    Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 Inhibition in a Subset of Sarcoma Cell Lines Increases Susceptibility to Radiation Therapy by Inducing Senescence in the Polyploid Cells.
    Das S
    Adv Radiat Oncol; 2020; 5(2):250-259. PubMed ID: 32280825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors.
    Li WF; Alfason L; Huang C; Tang Y; Qiu L; Miyagishi M; Wu SR; Kasim V
    Acta Pharmacol Sin; 2023 Mar; 44(3):647-660. PubMed ID: 35995868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA.
    Galehdar Z; Swan P; Fuerth B; Callaghan SM; Park DS; Cregan SP
    J Neurosci; 2010 Dec; 30(50):16938-48. PubMed ID: 21159964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner.
    Shuvalov O; Kizenko A; Shakirova A; Fedorova O; Petukhov A; Aksenov N; Vasileva E; Daks A; Barlev N
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1233-1239. PubMed ID: 29175211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.
    Vaseva AV; Marchenko ND; Moll UM
    Cell Cycle; 2009 Jun; 8(11):1711-9. PubMed ID: 19411846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
    Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
    Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
    Ray-Coquard I; Blay JY; Italiano A; Le Cesne A; Penel N; Zhi J; Heil F; Rueger R; Graves B; Ding M; Geho D; Middleton SA; Vassilev LT; Nichols GL; Bui BN
    Lancet Oncol; 2012 Nov; 13(11):1133-40. PubMed ID: 23084521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics.
    Tian X; El-Deiry WS
    Oncotarget; 2024 Sep; 15():614-633. PubMed ID: 39288289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
    Babcock JT; Nguyen HB; He Y; Hendricks JW; Wek RC; Quilliam LA
    J Biol Chem; 2013 May; 288(22):15687-98. PubMed ID: 23612979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
    Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
    BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.
    Obrador-Hevia A; Martinez-Font E; Felipe-Abrio I; Calabuig-Fariñas S; Serra-Sitjar M; López-Guerrero JA; Ramos R; Alemany R; Martín-Broto J
    Cancer Invest; 2015; 33(9):440-50. PubMed ID: 26288114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.